Antipsychotic drugs:challenges and future directions by Howes, Oliver D. & Kaar, Stephen J.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/wps.20522
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Howes, O. D., & Kaar, S. J. (2018). Antipsychotic drugs: challenges and future directions. World Psychiatry,
17(2), 170-171. https://doi.org/10.1002/wps.20522
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Antipsychotic drugs: challenges and future directions 
 
Some sixty years on from the first use of chlorpromazine to treat schizophrenia, it is worth 
reflecting on where we have come from. Back in the 1950s it was not known that dopamine 
was a neurotransmitter, how antipsychotics worked, what symptoms they worked on, or 
indeed if they worked at all1. Now we know that dopamine is a neurotransmitter, 
antipsychotics are all dopamine receptor blockers and, as Correll et al2 nicely review, large 
randomized, double-blind placebo-controlled trials have unequivocally demonstrated that 
they work both to treat acute psychotic episodes and to reduce relapse rates over the short 
to medium term.  
Recent meta-analytic data generated from over sixty years of placebo-controlled trials 
estimate the standardized mean difference (SMD) between antipsychotics and placebo to be 
0.38, with a greater effect seen on positive symptoms (SMD=0.45) than negative symptoms 
(SMD=0.35), quality of life (SMD=0.35) or depression (SMD=0.27)3. Such effect sizes are 
comparable to or larger than those found for treatments used for many common physical 
health conditions, including angiotensin-converting enzyme (ACE) inhibitors for reducing 
cardiac events and mortality due to hypertension (SMD=0.16) and statins for reducing the risk 
of cardiac disease and stroke (SMD=0.15)4. Clearly, we have come a long way from the 1950s, 
but, despite these robust data on antipsychotics, many fundamental gaps in knowledge 
remain.  
One glaring gap highlighted in this Forum is that as of yet we are unable to say 
conclusively what the optimum length of treatment with antipsychotic medication should be, 
once a patient has recovered from an acute episode. In current practice, many patients are 
treated with antipsychotic medication long-term if not lifelong, in an attempt to prevent the 
frequency and severity of relapses that can be so disruptive to a person’s life.  
Where patients are symptom free but experiencing side-effects such a weight gain that 
may shorten life as well as affect its quality, the risk-benefit balance for relapse prevention is 
finely poised. Yet, as Correll et al highlight, there is little evidence from randomized, double 
blind controlled studies to support prophylactic treatment beyond two-three years. Whilst 
some naturalistic studies do provide support for treatment beyond this term, the inherent 
limitations of these designs mean that the question remains unresolved, and guidelines 
cannot be conclusive.  
This is a challenge to the field which needs to be met. We will need longer and, crucially, 
larger randomized controlled studies. This will not be easy, but other fields have risen to the 
challenge. For example, in the case of the examples discussed above, statins and ACE 
inhibitors, there are now a number of randomized placebo-controlled trials with several 
thousand patients. These studies are roughly two orders of magnitude larger and five to ten 
times longer than the typical long-term randomized controlled study in schizophrenia. These 
large sample sizes give the power to have extended follow-up and account for treatment 
changes and drop-out. It is likely that we will need new ways of working, including 
international academic consortia as well as partnership with the pharmaceutical industry and 
governments, to achieve such large-scale studies.  
Correll et al also highlight heterogeneity in schizophrenia, something that is increasingly 
becoming apparent in the neurobiology underlying the disorder as well as its clinical 
manifestations, course and treatment response5.  
Treatment resistance is probably the most clinically important manifestation of 
heterogeneity in patients with schizophrenia, and remains a major issue that continues to 
provoke debate over its pathophysiology, diagnosis and clinical management6. About a third 
of patients are thought to have treatment resistant illnesses, and around 15% show treatment 
resistance from illness onset7. Moreover, we have no way to identify the individuals whose 
illness will benefit from antipsychotic treatment.  
Thus, currently large numbers of patients receive antipsychotic treatment although their 
illness is unlikely to respond to dopamine antagonists. The solutions to this will likely be found 
in part through identifying biomarkers that allow disease stratification, for example by the 
likelihood of response to dopamine receptor antagonists and, in the future, novel non-
dopamine receptor blocking medication.  
As both trial data and clinical experience show, current antipsychotic treatment works 
most effectively in reducing the positive symptoms of schizophrenia, whereas the negative 
and cognitive symptoms often remain problematic. Cognitive symptoms in particular are 
associated with poor functional outcomes in schizophrenia8, yet our current treatments do 
little for them. In fact, there is evidence to suggest that dopamine antagonists may cause 
secondary negative and cognitive symptoms in people with schizophrenia9. Put simply, taking 
an antipsychotic may be unpleasant for some patients, and lead to secondary symptoms. This 
highlights the third challenge to the field: the need to develop treatments that are more than 
just antipsychotic and that patients are happy to take in the long term if necessary.  
The final challenge is that our current antipsychotic medications are not disease 
modifying. Pre-synaptic striatal dopamine dysfunction is thought to drive the symptoms of 
schizophrenia10, yet all of our current antipsychotic drugs act post-synaptically. Thus, they 
block the consequences of pre-synaptic dopamine dysfunction but do not address the 
underlying dopamine dysfunction, which remains present even after long-term treatment. 
This provides a neurobiological explanation for why patients may relapse on stopping 
antipsychotic treatment.  
Targeting the upstream abnormality and/or the factors that lead to it is an alternative 
approach that could both be better tolerated and more effective in the long term. Broadly 
speaking, the glutamatergic and GABAergic systems have excitatory and inhibitory effects, 
respectively, on the dopamine system. Genetic studies measuring copy number variants in 
patients with schizophrenia11 suggest that abnormalities in both neurotransmitter systems 
may be critical to the upstream regulation of dopamine. Findings like these suggest that 
targeting GABA and glutamate control of subcortical dopamine function could modify the 
pathophysiology, and potentially even be disease modifying. The interaction between 
psychosocial factors and biological changes12 also highlights the potential for psychological 
treatments to be disease modifying.   
It is clear that we have come a long way from the 1950s in terms of both understanding 
of the pathophysiology of schizophrenia and its treatment, and this has thrown up new 
questions and issues. Antipsychotic drugs are likely to remain a crucial part of our therapeutic 
arsenal for years to come, so it behoves us to address the questions that remain. 
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